Comments
Loading...

Pfizer Analyst Ratings

PFENYSE
Logo brought to you by Benzinga Data
$24.19
-0.05-0.21%
At close: -
$24.21
0.020.08%
After Hours: 6:36 PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$50.00
Lowest Price Target1
$24.00
Consensus Price Target1
$33.32

Pfizer Analyst Ratings and Price Targets | NYSE:PFE | Benzinga

Pfizer Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Pfizer Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Jan
1
1
Feb
2
Mar
4
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.6
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

UBS
Cantor Fitzgerald
Goldman Sachs
UBS
Citigroup

1calculated from analyst ratings

Analyst Ratings for Pfizer

Buy NowGet Alert
04/30/2025Buy NowUBS
Trung Huynh71%
$24 → $25MaintainsNeutralGet Alert
04/22/2025Buy NowCantor Fitzgerald
Carter Gould56%
→ $24Initiates → NeutralGet Alert
04/08/2025Buy NowUBS
Trung Huynh71%
$28 → $24MaintainsNeutralGet Alert
04/08/2025Buy NowGoldman Sachs
Asad Haider 57%
$32 → $25DowngradeBuy → NeutralGet Alert
03/18/2025Buy NowGuggenheim
Vamil Divan74%
ReiteratesBuy → BuyGet Alert
03/12/2025Buy NowGuggenheim
Vamil Divan74%
ReiteratesBuy → BuyGet Alert
02/10/2025Buy NowGuggenheim
Vamil Divan74%
$33 → $33ReiteratesBuy → BuyGet Alert
02/05/2025Buy NowUBS
Colin Bristow39%
$29 → $28MaintainsNeutralGet Alert
01/28/2025Buy NowCitigroup
Andrew Baum69%
$30 → $29MaintainsNeutralGet Alert
01/08/2025Buy NowUBS
Colin Bristow39%
$31 → $29MaintainsNeutralGet Alert
12/18/2024Buy NowTruist Securities
Srikripa Devarakonda41%
$36 → $32MaintainsBuyGet Alert
12/11/2024Buy NowGuggenheim
Vamil Divan74%
$35 → $33MaintainsBuyGet Alert
12/10/2024Buy NowB of A Securities
Tim Anderson66%
→ $29Reinstates → NeutralGet Alert
11/15/2024Buy NowWolfe Research
Alexandria Hammond45%
→ $25Initiates → UnderperformGet Alert
10/30/2024Buy NowMorgan Stanley
Terence Flynn64%
$30 → $31MaintainsEqual-WeightGet Alert
10/25/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
10/23/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
10/17/2024Buy NowBernstein
Courtney Breen1%
→ $32Initiates → Market PerformGet Alert
10/11/2024Buy NowMorgan Stanley
Terence Flynn64%
$31 → $30MaintainsEqual-WeightGet Alert
10/03/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
09/16/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
08/19/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
08/08/2024Buy NowDaiwa Capital
Narumi Nakagiri23%
$28 → $34UpgradeNeutral → OutperformGet Alert
07/31/2024Buy NowMorgan Stanley
Terence Flynn64%
$29 → $31MaintainsEqual-WeightGet Alert
07/31/2024Buy NowBarclays
Carter Gould56%
$30 → $32MaintainsEqual-WeightGet Alert
07/31/2024Buy NowWells Fargo
Mohit Bansal67%
$28 → $30MaintainsEqual-WeightGet Alert
07/31/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
07/31/2024Buy NowUBS
Colin Bristow39%
$30 → $31MaintainsNeutralGet Alert
07/12/2024Buy NowUBS
Colin Bristow39%
$28 → $30MaintainsNeutralGet Alert
07/10/2024Buy NowBarclays
Carter Gould56%
$28 → $30MaintainsEqual-WeightGet Alert
07/10/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
07/01/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/26/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/20/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/17/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
05/02/2024Buy NowMorgan Stanley
Terence Flynn64%
$28 → $29MaintainsEqual-WeightGet Alert
05/02/2024Buy NowBMO Capital
Evan David Seigerman46%
$33 → $36ReiteratesOutperform → OutperformGet Alert
04/18/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/15/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/05/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/01/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/31/2024Buy NowMorgan Stanley
Terence Flynn64%
$28 → $29MaintainsEqual-WeightGet Alert
03/22/2024Buy NowArgus Research
David Toung68%
DowngradeBuy → HoldGet Alert
03/04/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/01/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
02/23/2024Buy NowGuggenheim
Vamil Divan74%
→ $36Initiates → BuyGet Alert
01/31/2024Buy NowUBS
Colin Bristow39%
$29 → $28MaintainsNeutralGet Alert
01/31/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
01/17/2024Buy NowUBS
Colin Bristow39%
$27 → $29MaintainsNeutralGet Alert
01/09/2024Buy NowCantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
01/04/2024Buy NowTD Cowen
Steve Scala67%
→ $32DowngradeOutperform → Market PerformGet Alert
12/14/2023Buy NowWells Fargo
Mohit Bansal67%
$35 → $28MaintainsEqual-WeightGet Alert
12/14/2023Buy NowCantor Fitzgerald
Louise Chen56%
$75 → $45MaintainsOverweightGet Alert
12/14/2023Buy NowTruist Securities
Robyn Karnauskas54%
$42 → $36MaintainsBuyGet Alert
12/14/2023Buy NowUBS
Colin Bristow39%
$34 → $27MaintainsNeutralGet Alert
12/14/2023Buy NowBarclays
Carter Gould56%
$34 → $28MaintainsEqual-WeightGet Alert
12/04/2023Buy NowTruist Securities
Robyn Karnauskas54%
→ $42ReiteratesBuy → BuyGet Alert
11/20/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
11/01/2023Buy NowBarclays
Carter Gould56%
$35 → $34MaintainsEqual-WeightGet Alert
11/01/2023Buy NowMorgan Stanley
Terence Flynn64%
$39 → $37MaintainsEqual-WeightGet Alert
10/20/2023Buy NowUBS
Colin Bristow39%
$36 → $34AssumesNeutral → NeutralGet Alert
10/17/2023Buy NowTruist Securities
Robyn Karnauskas54%
$62 → $42MaintainsBuyGet Alert
10/17/2023Buy NowMorgan Stanley
Terence Flynn64%
$40 → $39MaintainsEqual-WeightGet Alert
10/17/2023Buy NowWells Fargo
Mohit Bansal67%
$39 → $35MaintainsEqual-WeightGet Alert
10/16/2023Buy NowBMO Capital
Evan David Seigerman46%
$44 → $33MaintainsOutperformGet Alert
10/16/2023Buy NowCitigroup
Andrew Baum69%
$42 → $35MaintainsNeutralGet Alert
10/16/2023Buy NowJP Morgan
Chris Schott59%
$36 → $34MaintainsNeutralGet Alert
10/16/2023Buy NowWells Fargo
Mohit Bansal67%
$39 → $35MaintainsEqual-WeightGet Alert
10/16/2023Buy NowJefferies
Akash Tewari43%
$38 → $39UpgradeHold → BuyGet Alert
10/06/2023Buy NowJP Morgan
Chris Schott59%
$39 → $36MaintainsNeutralGet Alert
10/02/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
09/18/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
09/13/2023Buy NowTruist Securities
Robyn Karnauskas54%
→ $62ReiteratesBuy → BuyGet Alert
09/05/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
08/30/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
08/22/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
08/02/2023Buy NowTruist Securities
Robyn Karnauskas54%
$64 → $62MaintainsBuyGet Alert
08/02/2023Buy NowMorgan Stanley
Terence Flynn64%
$42 → $40MaintainsEqual-WeightGet Alert
08/02/2023Buy NowBMO Capital
Evan David Seigerman46%
$45 → $44MaintainsOutperformGet Alert
07/21/2023Buy NowMorgan Stanley
Terence Flynn64%
$43 → $42MaintainsEqual-WeightGet Alert
07/14/2023Buy NowHSBC
Rajesh Kumar61%
→ $50Initiates → BuyGet Alert
07/11/2023Buy NowMorgan Stanley
Terence Flynn64%
$43 → $43ReiteratesEqual-Weight → Equal-WeightGet Alert
07/11/2023Buy NowBarclays
Carter Gould56%
$40 → $38MaintainsEqual-WeightGet Alert
06/29/2023Buy NowCredit Suisse
Trung Huynh71%
$47 → $40DowngradeOutperform → NeutralGet Alert
06/23/2023Buy NowCantor Fitzgerald
Louise Chen56%
$75 → $75ReiteratesOverweight → OverweightGet Alert
06/22/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
05/17/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
05/11/2023Buy NowDaiwa Capital
Narumi Nakagiri23%
$51 → $38DowngradeOutperform → NeutralGet Alert
05/03/2023Buy NowCredit Suisse
Trung Huynh71%
$50 → $47MaintainsOutperformGet Alert
05/03/2023Buy NowBarclays
Carter Gould56%
$43 → $40MaintainsEqual-WeightGet Alert
04/21/2023Buy NowB of A Securities
Geoff Meacham62%
$50 → $45MaintainsNeutralGet Alert
04/12/2023Buy NowBarclays
Carter Gould56%
$44 → $43MaintainsEqual-WeightGet Alert
04/10/2023Buy NowMorgan Stanley
Terence Flynn64%
$45 → $44MaintainsEqual-WeightGet Alert
03/17/2023Buy NowWells Fargo
Mohit Bansal67%
$50 → $44MaintainsEqual-WeightGet Alert
03/06/2023Buy NowJefferies
Akash Tewari43%
→ $43Initiates → HoldGet Alert
02/07/2023Buy NowDaiwa Capital
Narumi Nakagiri23%
→ $51UpgradeNeutral → OutperformGet Alert
02/01/2023Buy NowMorgan Stanley
Terence Flynn64%
$53 → $45MaintainsEqual-WeightGet Alert
02/01/2023Buy NowCantor Fitzgerald
Louise Chen56%
→ $75Reiterates → OverweightGet Alert
02/01/2023Buy NowCredit Suisse
Trung Huynh71%
$54 → $50MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Pfizer (PFE) stock?

A

The latest price target for Pfizer (NYSE:PFE) was reported by UBS on April 30, 2025. The analyst firm set a price target for $25.00 expecting PFE to rise to within 12 months (a possible 3.26% upside). 33 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Pfizer (PFE)?

A

The latest analyst rating for Pfizer (NYSE:PFE) was provided by UBS, and Pfizer maintained their neutral rating.

Q

When was the last upgrade for Pfizer (PFE)?

A

The last upgrade for Pfizer Inc happened on August 8, 2024 when Daiwa Capital raised their price target to $34. Daiwa Capital previously had a neutral for Pfizer Inc.

Q

When was the last downgrade for Pfizer (PFE)?

A

The last downgrade for Pfizer Inc happened on April 8, 2025 when Goldman Sachs changed their price target from $32 to $25 for Pfizer Inc.

Q

When is the next analyst rating going to be posted or updated for Pfizer (PFE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.

Q

Is the Analyst Rating Pfizer (PFE) correct?

A

While ratings are subjective and will change, the latest Pfizer (PFE) rating was a maintained with a price target of $24.00 to $25.00. The current price Pfizer (PFE) is trading at is $24.21, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch